应用肝脏加速容积采集增强序列提高新辅助放化疗后直肠黏液腺癌器官侵犯再评估的准确性
本研究回顾性纳入25例新辅助治疗后行根治性切除术的直肠黏液腺癌患者,比较T2加权联合扩散加权成像(T2Dw方案)与再加肝脏加速容积采集增强序列(T2DwLce方案)再评估器官侵犯的准确性。T2Dw方案准确率为44.0%(11/25),低于非黏液性直肠腺癌的94.1%(96/102);T2DwLce方案准确率为23/25,AUC为0.857(95%CI 0.660~0.964),高于T2Dw方案的AUC 0.611(95%CI 0.397~0.798)(P=0.019)。作者认为LAVA-ce序列可提高再评估准确性,应纳入黏液腺癌患者的MRI方案。
要点
- 直肠黏液腺癌新辅助治疗后T2Dw方案再评估器官侵犯准确率仅44.0%(11/25)。
- 加用LAVA-ce序列后准确率提高至23/25,AUC由0.611升至0.857(P=0.019)。
- 作者认为LAVA-ce应纳入黏液腺癌患者MRI方案。
核心结论
- LAVA-ce序列可提高直肠黏液腺癌新辅助治疗后器官侵犯再评估的准确性,作者认为应将其纳入该类患者的MRI方案。
研究设计与样本
- 回顾性纳入25例直肠黏液腺癌患者(男15例、女10例,年龄21~89岁),均在新辅助治疗前后行MRI、新辅助治疗前T2加权成像分期为T4b并接受根治性切除术。
- 所有MR图像分为两套方案:T2加权联合扩散加权成像(T2Dw方案)与再加LAVA-ce序列(T2DwLce方案)。
- 以术后病理识别周围器官侵犯(ypT4b)为参考标准,用0~4分评估器官侵犯性黏液成分,采用受试者工作特征曲线及曲线下面积评价与病理的一致性。
诊断标准与关键数值
- T2Dw方案将25例中21例再分期为yT4b,准确率为44.0%(11/25),低于非黏液性直肠腺癌的94.1%(96/102)。
- T2DwLce方案再评估准确率为23/25。
- T2DwLce方案AUC为0.857(95%CI 0.660~0.964),高于T2Dw方案的AUC 0.611(95%CI 0.397~0.798)(P=0.019)。
临床应用与阅片要点
- 对直肠黏液腺癌新辅助治疗后器官侵犯的再评估,作者认为应将LAVA-ce序列纳入MRI方案以提高准确性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To explore the ability of liver acquisition with volume acceleration contrast-enhanced sequence (LAVA-ce) to improve the accuracy of reassessing adjacent organ involvement by rectal mucinous adenocarcinoma (MC) after neoadjuvant therapy (NAT).
METHODS: This study retrospectively enrolled twenty-five patients with MC who underwent pre- and post-NAT MRI, were staged as T4b using pre-NAT T2 weighted imaging, received NAT and underwent radical resection. All MR images were divided into two schemes, T2 weighted plus diffusion weighted imaging (T2Dw protocol) and plus LAVA-ce (T2DwLce protocol). All patients were scored on a 0-4 scale to reassess organ-invasive mucus components. Postoperative pathology was used to identify the involvement of surrounding organs (ypT4b). The receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to evaluate the consistency of the results with pathology after adding fs-CE sequence.
RESULTS: Among 25 MC patients (15 males and 10 females, aged 21-89 years), 21 were restaged as yT4b after NAT by using T2Dw, with an accuracy of 44.0 % (11/25), which was lower than the accuracy of staging patients with non-mucinous rectal adenocarcinoma (94.1 %, 96/102). The accuracy of MC restaging was improved by using T2DwLce (23/25). The AUC of T2DwLce was 0.857 (95 % CI, 0.660∼0.964), which was higher than that of T2Dw (AUC, 0.611 [95 % CI, 0.397∼0.798]) (P = 0.019).
CONCLUSION: The LAVA-ce sequence can improve the accuracy of reevaluation and should be included in the MRI protocol for MC patients.
引用
- Cao W, Zou Q, Zhao Y, et al. Application of liver acquisition with volume acceleration enhanced sequence in improving the accuracy of reassessing organ-invasive rectal mucinous adenocarcinoma after chemoradiation. Eur J Radiol. 2020. PMID: 33207287. doi:10.1016/j.ejrad.2020.109368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。